RenovoRx RNXT 深 滬
已收盤 09-05 16:00:00 美东时间
1.24
+0.050
+4.20%
華盛通- 最 高1.25
- 今 開1.22
- 成交量 50.96万股
- 最 低 1.16
- 昨 收 1.19
- 總市值 4544.09万
- 52周最高 1.6899
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.75
- 委 比 -24.61%
- 總股本 3664.59万
- 歷史最高 16.74
- 量 比 0.71
- 振 幅 7.56%
- 歷史最低 0.5306
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SRx Health Solutions Signed a Letter of Intent to Acquire the Assets of Royal Uranium
SRx Health Solutions, Inc. has signed a non-binding Letter of Intent to acquire 100% of Royal Uranium Inc.'s assets, expanding its mission to combine hard-asset energy royalties amid surging AI and data center power demand. The deal, subject to customary closing conditions, includes 18 uranium royalties across key jurisdictions. The acquisition aims to capitalize on global clean energy transition and growing demand for nuclear energy, with strate...
08-18 11:00
RenovoRx Announces The Independent Data Monitoring Committee For Its Ongoing Phase III TIGeR-PaC Trial Has Recommended To Continue The Study
"At the same time, we are very excited to report that the independent Data Monitoring Committee (DMC) for our ongoing Phase III TIGeR-PaC trial recently completed their review of our second pre-planned interim analysis
08-15 04:18
RenovoRx Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $422.00K Beat $329.67K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 8.05 percent. This is a 20 percent increase over losses of $(0.10) per share from the same
08-15 04:12
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
RenovoRx Expands RenovoCath Commercial Reach To 13 Cancer Centers
RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCathFour active cancer center customers are currently purchasing and
08-06 20:38
RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire
<p>RenovoRx expands its commercial presence with 13 cancer centers approved to purchase RenovoCath, including 4 repeat customers. The company hires Philip Stocton as Senior Director of Sales, leveraging his 25+ years in MedTech and interventional oncology. This growth underscores the demand for localized tumor treatments beyond traditional IV chemotherapy. RenovoCath's adoption highlights its potential to improve patient outcomes by reducing syst...
08-06 12:30
RenovoRx Launches PanTheR Post-Marketing Registry Study, To Expand Safety And Performance Data Of FDA-Cleared RenovoCath Device, And Associated Survival Outcomes In Patients Diagnosed With Solid Tumors
Several Esteemed Cancer Centers to Commence Patient Enrollment Before the End of SeptemberThe Registry Study, Known as PanTheR, will Expand the Safety and Performance Data of the FDA-Cleared RenovoCath® Device, and
07-28 20:36
美股大行评级 | 潜在涨幅6326.33%！Ascendiant Capital上调Plus Therapeutics目标价至20.5美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137665801621229569.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Plus Therapeutics(PSTV)"买入"评级，目标价从20美元升至20.5美元</p> <p>• Ascendiant Capital：维持RenovoRx(RNXT
06-06 09:45
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $11.5
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $11 to $11.5.
06-05 18:33
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
